FCS Accelerates Next Generation of Targeted Cancer Therapies
Florida Cancer Specialists & Research Institute Accelerates Next Generation of Targeted Cancer Therapies
Drug Development Leaders Share RAS Findings at Global Symposium
Fort Myers, Fla., November 18, 2026 – Studies of emerging approaches to targeting RAS mutations, including two first-in-human clinical trials, conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) are being presented at the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics this week in Barcelona, Spain.
RAS (Rat sarcoma) genes help regulate cell growth, division and signaling. Mutations in these genes, particularly KRAS, NRAS and HRAS, contribute to the development of several common and historically difficult-to-treat cancers, including colorectal, lung and pancreatic cancers.
“Targeting RAS mutations is a major priority in advancing the next generation of cancer therapies,” said Manish R. Patel, MD, who directs activities at the statewide practice’s two drug development units in Sarasota and Central Florida dedicated exclusively to Phase 1 clinical trials in partnership with Sarah Cannon Research Institute (SCRI). Dr. Patel is co-author of the following abstract being presented at ENA 2026:
- A First-in-Human Phase 1/2 Study of SAR449336, an Oral Non-Covalent Pan-KRAS Inhibitor, in Patients With Advanced KRAS-Mutant Solid Tumors (Trial in Progress) (338)
Associate Director of Drug Development Judy Wang, MD, who oversees clinical trials offered at the FCS Sarasota Drug Development Unit and serves as principal investigator on a multitude of early-phase trials, will deliver the following oral presentations:
- Preliminary safety, pharmacokinetics, and efficacy of ERAS-0015: Results from the AURORAS-1 first-in human trial (8)
- Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor, in patients with KRASG12D-mutated endometrial cancer (9LBA)
“I am honored to present our research alongside global leaders in drug development and contribute to the scientific exchange that is advancing our understanding of cancer biology, emerging therapeutic targets and new treatment approaches,” Dr. Wang said.
Additionally, Dr. Wang and Cesar Perez, MD, director of the Drug Development Unit at the Sarah Cannon Research Institute at FCS in Lake Nona, contributed to the following abstract being presented at ENA 2026:
- Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of ACZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors (81)
“Our continued commitment to clinical research reinforces the important role community oncology plays in advancing cancer care and bringing access to new therapies closer to where patients live,” added Dr. Wang.
Through partnerships with SCRI—one of the world’s leading oncology research organizations conducting community-based clinical trials—and Paradigm Health, Inc., FCS offers convenient access to clinical trials at nearly 30 locations statewide, including its drug development units.
All accepted abstracts will be published online at ENA2026.